While sialylated carbohydrate antigen KL-6 (KL-6) is usually used as a biomarker to evaluate lung fibrosis and can predict severity in patients with COVID-19, there was no significant difference between PMV and non-PMV in our study [28]. The gene discussed is MUC1; the disease is pulmonary fibrosis.